Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting pathways mediating bone disease.

Nicola Giuliani1, Francesca Morandi, Sara Tagliaferri

  • 1Hematology and BMT Center, Department of Internal Medicine and Biomedical Science, University of Parma, Italy. ngiulia4@ipruniv.cce.unipr.it

Current Pharmaceutical Biotechnology
|December 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study.

Annals of hematology·2026
Same author

Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma.

Haematologica·2026
Same author

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

Haematologica·2026
Same author

A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth.

Blood neoplasia·2026
Same author

Changes in human multifidus muscle size with aging and short-term disuse.

Experimental gerontology·2026
Same author

Advances in the pathophysiology and treatment of anaemia in multiple myeloma.

Current opinion in hematology·2026
Same journal

Bioactivity and Bioavailability of Tea (Camelia sinensis) and Its Possible Effect on Disease Prevention and Health Promotion: A Narrative Review.

Current pharmaceutical biotechnology·2026
Same journal

Therapeutic Applications and Advancements of Exosome-Based Treatments - A Comprehensive Review.

Current pharmaceutical biotechnology·2026
Same journal

Comparative Phytochemical Characterization and Antibacterial Activity of Ethanol and Aqueous Extracts of Moringa peregrina and Moringa oleifera against Multidrug-Resistant Bacteria.

Current pharmaceutical biotechnology·2026
Same journal

Unveiling Aptamers for Targeted Tumour Therapies and Detection: Systematic Evolution of Ligands by Exponential Enrichment (SELEX) Technology in Oncology.

Current pharmaceutical biotechnology·2026
Same journal

Nanosuspensions-Based Dry Powder Inhalers for Pulmonary Delivery of Hydrophobic Natural Products: Formulation Strategies, Efficacy, and Challenges.

Current pharmaceutical biotechnology·2026
Same journal

Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Accelerate Diabetic Rat Wound Healing by Inhibiting Pyroptosis through the NLRP3/Caspase-1/GSDMD Pathway.

Current pharmaceutical biotechnology·2026
See all related articles

Multiple myeloma causes bone lesions by increasing osteoclast activity and decreasing bone formation. Understanding this mechanism helps develop new treatments for skeletal complications in multiple myeloma patients.

Area of Science:

  • Oncology
  • Bone Biology
  • Pathophysiology

Background:

  • Multiple myeloma (MM) is a plasma cell cancer known for causing significant bone destruction.
  • Bone lesions in MM result from increased osteoclast activity and decreased osteoblast function.
  • Myeloma cell infiltration directly correlates with the severity of bone loss and reduced bone formation.

Purpose of the Study:

  • To summarize the pathophysiology of bone destruction in multiple myeloma.
  • To highlight the role of osteoclast and osteoblast imbalance in MM-induced osteolysis.
  • To underscore the importance of understanding MM bone disease for therapeutic development.

Main Methods:

  • Review of histomorphometric studies in multiple myeloma patients.
  • Analysis of the relationship between plasma cell infiltrate and bone remodeling.

Related Experiment Videos

  • Synthesis of current knowledge on MM pathophysiology and therapeutic targets.

    • Main Results:

    • High plasma cell infiltration in MM is associated with reduced osteoblast numbers and decreased bone formation.
    • Osteoclast hyperactivity, driven by myeloma cells, is a primary driver of osteolytic lesions.
    • The interplay between myeloma cells, osteoclasts, and osteoblasts dictates bone lesion development.

    Conclusions:

    • Targeting the mechanisms of MM-induced osteolysis is crucial for managing skeletal complications.
    • Advances in understanding MM pathophysiology have identified new therapeutic targets for bone disease.
    • New drugs are emerging for treating skeletal involvement in multiple myeloma patients.